Speakers

Qualified with a hospital pharmacy background, Omar has been working as the Formulary Advisor for Surrey & Sussex Healthcare NHS Trust for over 15 years, sitting on the regional Joint Drugs & Therapeutics Committee as well as the CCG/Commissioning Prescribing Clinical Network. Omar has...

Tibor is the Director of Sales and Business Development at Kuhner AG, Switzerland. In 2001, he gained a PhD in biochemical engineering, focusing on online monitoring in shaken bioreactors, RWTH Aachen, Germany. The same year, he achieved the Award of the Technical University of Aachen...

Dr George Badescu is Vice President Scientific Affairs at Heidelberg Pharma and has over 15 years of experience in the biotechnology sector. He most recently served as Vice President Scientific Affairs at Abzena Plc where he led the scientific promotion and commercialization of Abzena?s...

Dr. Flechtner joined Genocea in 2007, soon after the company was founded, and currently serves as Chief Scientific Officer. She has more than 20 years of experience in immunology, cancer, infectious disease, vaccine and cell therapy development. She leads Genocea’s efforts to develop personalized T ...

Marta Baldrighi joined Medicines for Europe in 2020, where she works as Policy and Science Officer in the Biosimilar Medicines and Value Added Medicines Groups. Medicines for Europe represents the pharmaceutical companies supplying the largest share of medicines across Europe and is the voice of...

Dr. Alexander Baumann heads the development of Eurofins DiscoverX’s product business in Europe. His focus areas are cell-based assays, supporting biologics and small molecule therapeutics development from discovery to lot release, as well as custom production and bioassay cell banking.  Alexander...

Dr. Roger R. Beerli (CSO of NBE-Therapeutics AG, a wholly owned subsidiary of Boehringer-Ingelheim) has over 20 years of experience in the discovery, engineering and preclinical development of antibody-based therapeutics. Before he joined NBE-Therapeutics AG, he led therapeutic antibody development ...

Stephen Beers, PhD, Professor of Immunology and Immunotherapy, Centre for Cancer Immunology, School of Cancer Sciences, University of SouthamptonStephen Beers is Professor of Immunology and Immunotherapy at the Centre for Cancer Immunology, University of Southampton. He leads a research group...

Ahmed Besheer has extensive experience in drug product development, with more than 10 years in the pharmaceutical industry. Before joining Lonza in 2018, Ahmed has been working at Novartis and Merck Serono in parenteral formulation development, as DP project lead and later as head of NBE...

Roza Bidshahri is a Senior Scientist and BD Liaison at AbCellera, a company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. Roza joined AbCellera in 2016 as a Senior Research Scientist to develop a ...

Dr. Bilinsky joined Iovance as Chief Operating Officer in March of 2021. He has more than 20 years of cumulative leadership experience through prior roles as Chief Executive Officer, Chief Operating Officer, and Chief Business Officer at companies within the life sciences industry. Most recently he ...

Dr Broderick has a broad background in the product development and device development DNA therapeutic and drug delivery field, with specific expertise in in vivo DNA vaccine animal studies and product development in relation to electroporation.  Her particular area of focus is electroporation...

Sebastian Bunk is a senior director at Immatics where he leads a team developing a pipeline of bispecific T cell-engaging receptor (TCER®) molecules. After joining Immatics in 2014, Sebastian focused on the establishment of innovative technologies for engineering of T-cell receptors and generation...

Ms. Ping Cao, Vice President of Business Development of Shanghai Henlius Biotech (Henlius).  Prior to Henlius, Ms. Cao worked at Tyger Scientific, Ferro, Bristol-Myer Squibb (BMS) and Abzena, and held positions of Director of Sales and Marketing, Sr. Manager of Business Development, Associate...

Samuele Cazzamalli studied Medicinal Chemistry at the University of Milan. During his doctoral studies at ETH Zürich in the group of Prof. Dario Neri (2015-2018), Samuele has generated novel Antibody-Drug Conjugate, Small Molecule-Drug Conjugate and Small Molecule-Radio Conjugate products for...

Head of Immunology, Víctor Cervera-Carrascón, has expertise in immunotherapy, particularly on the use of oncolytic viruses to enable immune checkpoint blockade and other T-cell related approaches. Víctor obtained a PhD in a Marie Skłodowska-Curie consortium (The Netherlands and Finland) in...

Brian Champion obtained his PhD from McGill University, Montreal, Canada and is currently Chief Scientific Officer at PsiOxus Therapeutics Ltd, Oxford, UK where he has been leading the scientific development of novel oncolytic virus-based, Tumor-Specific Immunogene (T-SIGn) therapies for the...

Eleni is an Associate Director of Immune Receptor Discovery in AgenTus Therapeutics, a cell therapy company focusing on the discovery, development, and commercialization of iNKT cells weaponized with CARs to advance cures for cancer patients. Eleni’s team not only lead the CAR discovery efforts in...

Dr. Maggie Cheang is a Team Leader of the Genomic Analysis – Clinical Trials in Division of Clinical Studies and the Institute of Cancer Research Clinical Trials and Statistics Unit (ICR-CTSU). Her research focus is to develop genomics classifiers for tumour subtypes and to determine their clinical ...

Roberto De Luca graduated in Biology at ETH Zürich. He performed his PhD studies at ETH Zürich focusing on the generation of antibody-cytokine fusion proteins for the treatment of tumors. Dr. De Luca is author of several peer-reviewed publications in international scientific journals.

Professor Fernando de Mora has been a Professor of Pharmacology at the Universitat Autonoma de Barcelona. He has a PhD in Immunopharmacology from the Universitat Autonoma de Barcelona. Fernando gained an MBA from the University of Chicago in 1999. Fernando is the Chairman of the Pharmacology...

Isabel is currently the Deputy Director of the Spanish Biosimilar Medicines Association, BIOSIM (2020-present); previously project manager in BIOSIM (2016-2020). PhD in Agricultural Engineering from the Polytechnic University of Madrid (2014), Master in Agroforestry Biotechnology from the...

Audrey has a background in organic chemistry and formulation with her engineering degree and experiences in pharmaceutical industry in Europe. In 2017, she joined McSAF as Chief Operating Officer where she coordinates the valorization and development of the product pipeline in close collaborations...

Dr. Dimitrov graduated and completed his PhD at the University of Sofia, Sofia, Bulgaria, and thereafter he worked in the Bulgarian Academy of Sciences where he defended his ScD and was Professor of Biophysics until he joined the National Cancer Institute (NCI) of the National Institutes of Health...

Jean-Cosme (JC) Dodart is SVP of Preclinical R&D at Vaxxinity. JC has over 20+ years of experience in Neuroscience drug discovery at both large Pharma (Lilly, Merck, Novartis) and small Biotech (Sage Therapeutics, Wave Life Sciences). He has a strong track record of success in drug discovery...

A biochemist by training, Achim has been working with bispecifics for over a decade, starting with NK cell engaging aptamers, to bispecific antibodies, bispecific ADCs balancing selectivty by avidity to technology development for their effective screening. Further interests lie in concept...

As R&D Director of GEROPHARM Roman establishing product development of the company?s portfolio. Joined GEROPHARM as a head of clinical trials department in Oct 2016. Successfully performed several clinical trials including hyperinsulinemic euglycemic clamps and bioequivalence, Phase III...

Louise has a very extensive background in the global Bio/pharmaceutical industry with more than 30 years of experience in R&D and Commercial Supply having held senior roles in GlaxoSmithKline as VP & Global Supply Chain Head, Biopharmaceuticals, where she also served as VP and Corporate...

Lindy is Professor of Cancer Immunotherapy at the University of Nottingham and CSO of Scancell Ltd. She has developed two vaccine platforms ImmunoBodyTM and ModitopeTM which induce potent killer CD8 T cells and and cytotoxic CD4 T cells to post-translational modifications respectively. The first...

2002-2007 Studied Biology (B.Sc.) and Biology with Biomedical Sciences (M.Sc.) at University of Applied Sciences Bonn-Rhein-Sieg2009-2015 PhD in Cell & Molecular Biology at RWTH Aachen University and German Aerospace Center - DLRSince 2016 BioPurification Specialist for South Germany at Pall...

Bill has more than 20 years’ experience in protein engineering and display technologies. Following positions at Pfizer and CAT, he joined Isogenica, where he co-invented CIS Display. He was CSO for Cyclogenix, specialising in cyclic peptides. He has returned to Isogenica as CSO, overseeing the...

Geoffrey ESTEBAN has an engineering degree in Food Science and biotechnology and has 12 years of experience in a small enterprise developing new technologies and new innovative sensors solutions for the biotechnology industry. Geoffrey has started his career in R&D and continued successfully...

Mourad FERHAT is the Product Manager for EMEA region for Isoplexis. Mourad has a PhD in Molecular and Cellular Biology and an expert knowledge in Cancer and Immuno-Oncology. Prior to joining Isoplexis, Mourad worked for several Lifesciences companies such as Invitrogen, Promega and more recently...

I am an M.D., specialist in Oncology and Immunology, and I serve as a professor of Human Biochemistry at the School of Medicine, Federico II University of Naples, Italy. In the last decade, my research has provided significant contributions to the elucidation of the role of FK506 binding proteins...

Federica Fraschetti has spent her entire career in the Pharmaceutical Industry, developing an expertise in Manufacturing of Sterile Drug Product (DP) and Secondary Packaging at Contract Manufacturing Organizations (CMOs). In her current position at MSD, Federica is responsible for overseeing DP...

Anne Goubier is Vice President Immunology at Tusk Therapeutics. She started her career at Merial (now Boehringer Animal Health), first as a veterinary scientist before rapidly progressing to head of the Immunology laboratory and of the adjuvant selection and validation platform. She has since...

Thomas Hach, MD, is Executive Director Patient Engagement for Cardiovascular, Renal & Metabolism (CRM) at Novartis. He is leading end-to-end patient engagement strategy and operations for the broad CRM portfolio at Novartis. Thomas also held positions of Global Brand Medical Director...

Serial entrepreneur that combines strong strategic, technological and managerial experience with proven track record of deal-making and fund-raising. During my career I achieved together with my different teams to bring four drug candidates from research to the clinics (up to phase...

Dr. Katherine Harris has followed her entrepreneurial spirit to work at start-up stage companies where she has thrived in fast-paced work environments, building high-performance teams and processes in the early phases of company formation and growth.  As a leader of pre-clinical research...

Dr. Hege joined Bristol Myers Squibb (BMS) as SVP, Early Clinical Development, Hematology/Oncology & Cell Therapy following the acquisition of Celgene in 2019. Previously, she spent 10 years at Celgene building the Early Clinical Development organization where her team advanced a pipeline of...

Andreas received his Ph.D. in biochemistry in the field of neurobiology and worked as an associate professor in the department of cardiovascular physiology at the University of Cologne (1995-1997). Between 2003-2013, Andreas (co-)founded and headed different biotech companies including Celonic...

Oliver Hill joined Apogenix in March 2006 and is leading the Drug Discovery Unit of the company. Apogenix’ main focus is the development of biotherapeutic drugs targeting the TNFR superfamily. Mr Hill is an expert for protein engineering, fusion proteins and recombinant antibody-formats. Prior to...

I am a DPhil student in Professor Charlotte Deane’s group at the University of Oxford researching and developing machine learning tools for therapeutic antibody design. Prior to my DPhil, I completed my MSci in Biochemistry at the University of Oxford and an MPhil in Biological Science at the MRC...

Gordon Humphreys is currently Chairperson of the First Board and of the Third Board of Appeal at EUIPO, from 2014 to 2019 he had been Chairperson of the Fifth Board of Appeal, having joined the Boards as a Member in 2005. He was Head of the Register Service from 2002-2005 and joined EUIPO’s Legal...

Professor Sophia Karagiannis is a translational cancer immunologist with academic and biotechnology experience in the USA and UK. She heads a cancer antibody discovery team focused on the crosstalk between patient immune cells and cancer and on the design of novel agents for solid tumours. Key...

Dr. Keirstead is an internationally known stem cell expert and has led therapy development for late stage cancers, immune disorders, motor neuron diseases, spinal cord injury and retinal diseases. He is the CEO of AIVITA Biomedical. He was previously CSO of Caladrius which acquired California Stem...

Linda Klauss joined Gyros Protein Technologies in 2017 as Field Application Specialist providing application support to the customers in the DACH area. Prior to joining Gyros Protein Technologies Linda worked as a research associate in preclinical development at several pharmaceutical companies in...

Russell LaMontagne is co-founder and Chief Executive Officer of Boston Immune Technologies and Therapeutics, Inc.  In addition to BITT, for the last ten years he has been organized a working group in partnership with Massachusetts General Hospital to promote clinical trials and new indications for...

Victor Le received the PhD degree in analytical chemistry from the University of Paris Saclay, Orsay, France, in 2019. He is currently a Postdoc in Novartis to develop the LC-MS Multi Attribute Method to monitor the potential quality attributes of therapeutic proteins. His research interests focus...

Line has a M.Sc.eng. degree in Biotechnology from the Technical University of Denmark. In her PhD she focuses on the discovery of cross-reactive and broadly neutralizing antibodies against neurotoxins from African and Asian elapid snakes.

Steven Lehrer brings over 30 years of experience starting, growing and running life science-based businesses focused on commercializing new technology and expanding businesses globally. Steve has extensive experience in pharmaceutical, biopharmaceutical and biosimilar...

Dr. Jeanette Leusen, received her PhD in 1995 at the University of Amsterdam (UvA), The Netherlands, studying neutrophils. Now she is PI on antibody therapy in the University Medical Center of an academic group of 22 FTE. She has co-authored 120 publications and is co-inventor on 10 patent...

Dr. Qingcong Lin is SVP of Biocytogen and CEO of Biocytogen Boston Corporation. Dr. Lin focuses on Biocytogen’s global business development for antibody discovery services, RenMab/RenLite licensing and therapeutic antibody co-development, and on providing gene targeting services and humanized mouse ...

Anne Ljungars holds a PhD in Immunotechnology from Lund University, Sweden and has 20+ years of experience from biotech industry, latest from BioInvent International AB, Sweden where she has coordinated discovery efforts in several antibody drug projects, presently in preclinical or clinical...

Steve obtained his PhD in Physical Organic Chemistry from the University College of Swansea in 1993 and is a chartered chemist and a member of the Royal Society of Chemistry. He has worked for SCIEX in various technical roles for over 20 years and has presented at over 80 international meetings...

Erica Lovett is a Research Scientist at AbCellera within the Molecular Biology team. Erica joined AbCellera in 2019, and she manages AbCellera's high throughput antibody production pipeline and coordinates the internal SARS-CoV-2 variant surveillance team. She obtained her MSc in Biology from...

Dr. Geoffrey Lynn is CEO and Co-founder of Avidea Technologies (Baltimore, MD). In this capacity, Dr. Lynn is leveraging his background in synthetic chemistry and cellular immunology to lead Avidea’s efforts to develop immunotherapies for cancer treatment that are enabled by innovations around two...

Erik Manting holds a MSc in Medical Biology and a PhD in Molecular Microbiology. He worked for a number of years as a post-doctoral researcher in the field of immunology before making a career switch to banking in 2001. He spent the next 15 years in different commercial and management roles and his ...

Krzysztof is currently in charge of antibody discovery at Light Chain Bioscience (previously Novimmune). Krzysztof holds a Ph.D. from the University of Lausanne, Switzerland

Dr. Nena Matscheko is a senior scientist and currently leading the cell and antibody interactions research team at Dynamic Biosensors GmbH. The Munich-based biotech company develops instruments for biomolecular interaction analysis. Their proprietary switchSENSE® technology is marketed in...

Prem Swaroop Mohanty is a Life Sciences Product Specialist and Product Marketing Manager at Benchling. He holds an MBA from UC Berkeley, a MS from U of Illinois, Chicago, and a B.Pharm from U of Mumbai. He has over 14 years of industry experience across biopharma R&D, strategy consulting, and...

Mio Muelthaler has earned his PhD in Molecular Biology at the University of Wuerzburg in Germany. His first work experience outside academia started in the late 90ties as a scientist in R&D at nanotype, a biotech start-up near Martinsried, where he contributed to the measurement of the smallest ...

Dr Mike Muenzberg received his M.D. from the Medical University of Vienna. He completed his clinical training in Austria, Canada, South Africa and Sweden and is a licensed specialist in Nuclear Medicine.For the past 20 years, Mike has been active in the Biotech/Pharma Industry and was working for...

Daniel Muthas is the Head of Data Science & Bioinformatics in early Respiratory & Immunology at AstraZeneca. He holds a PhD from Uppsala University Sweden and joined AstraZeneca after a post-doctoral fellowship at University of Dundee, UK. At AstraZeneca he leads a global team of data...

Dario Neri was born in Rome on 1. May 1963 and grew up in Siena (Italy). He studied Chemistry at the Scuola Normale Superiore of Pisa and earned a PhD in Chemistry from the Swiss Federal Institute of Technology (ETH Zürich), under the supervision of Professor Kurt Wüthrich. After a post-​doctoral...

Maximilian Nitschké is a Principle Scientific Researcher at Genentech. Maximilian has studied biology at the LMU in Munich and received his PhD from the Institute of Pharmaceutical Sciences at the ETH, Switzerland, in 2012. Maximilian moved to the University of California, San Francisco for his...

Sari Pesonen gained her PhD in biology from the University of Turku, Finland in 2007. She continued her academic career at the University of Helsinki and was awarded a three-year post-doctoral research post by the Academy of Finland. Sari is a co-author in 60+ peer-reviewed research papers and...

Dr. Michael Petrich is Perkin Elmer’s Subject Matter Expert for Atomic Spectroscopy in Europe, the Middle East, Africa and India. He holds a degree in chemistry (1987) and a PhD in natural sciences (1990) from the Technical University of Leipzig, Germany.For 29 years Dr. Michael Petrich has been...

Elke is currently working as a Scientist in the early stage bioprocess development department of Boehringer Ingelheim, where she focuses on downstream processing of monoclonal antibodies. A central part of her work is the optimization of purification strategies to improve product quality and to...

Dr. Quintás joined TCR² in 2017 as Chief Medical Officer. He brings nearly two decades of experience leading clinical strategy and regulatory filings for multiple oncology therapeutics resulting in market approval. Dr. Quintás was the clinical development head of the Cell & Gene Therapies Unit...

​​​​​​​Jonah completed a PhD in Biochemistry at Tufts University and postdoc at University of Wisconsin and the Salk Institute. He has 15 years’ experience in discovery, research and development of bispecific antibodies. He authored several patents and publications describing bispecific platforms...

Dr. Ulrich Rant received his PhD in biophysics (summa cum laude) from the Technical University Munich, Germany, in 2005. After a PostDoc at TU Munich and a research stay at the Fujitsu Laboratories Ltd., Japan, he became a group leader at TU Munich in 2007. Uli was awarded a Carl-von-Linde...

Dr Anurag S Rathore is an Institute Chair Professor at the Department of Chemical Engineering, Indian Institute of Technology, Delhi, India. He is also the Coordinator for the DBT COE for Biopharmaceutical Technology. His previous roles included management positions at Amgen Inc., Thousand...

Vijay is currently the Global Market Access Strategy – Senior Director at Biocon Biologics, a fast growing +US$700 million dedicated biosimilar company, working closely with the global commercial and executive leadership team. He’s responsible to lead, shape and build biosimilar Global Market...

Dr. Reed, Executive Vice President, serves as the global head of Pharmaceutical Research & Development for Sanofi, reporting to the CEO and participating as a member of the company’s Executive Committee.  Prior to joining Sanofi in May 2018, Dr. Reed served as global head of pharmaceutical...

Brent is our Vice President of Global Market Access and joined Autolus in October 2018. An industry veteran with over 25 years of broad cross-functional leadership experience in biotech/pharmaceutical sales, marketing, operations, and reimbursement. Skilled in building scalable commercial customer...

Tiago Rocca has been working at the Instituto Butantan for over 14 years and has assumed responsibilities in several other areas related to vaccines and biopharmaceuticals production, technology transfer, validation, and Quality Assurance. Pharmacist and post-graduated in Health Law at Public...

Aaron is CSO of the Biopharma Vertical at Twist Bioscience.  Prior to Twist, he served as Chief Scientific Officer of LakePharma, leading the California Antibody Center, which discovers novel antibody therapeutics for its clients. He also oversaw all discovery research functions both as Vice...

Dr. Thomas Schirrmann is CEO of YUMAB and COO of Corat Therapeutics. He is biochemist by training and holds a PhD in immunology. He has more than 20 years expertise in research for immunotherapies and antibody technologies and published 70+ scientific articles. Thomas is co-founder and CEO of...

Sebastian Schlicker has more than 15 years of experience in managing pharma R&D IT projects, specializing in the implementation of global enterprise software solutions for large molecule R&D. Sebastian oversees all major consulting and deployment projects globally at Genedata. Before...

Before joining PerkinElmer, Dr. Scholler obtained her Ph.D. in Biology at the University of Montpellier in France, and worked at Pfizer, Merck Millipore and Cisbio Bioassays. Pauline has always worked on developing biochemical & cell-based assays using different technologies to investigate key...

Arnold completed his apprenticeship as a lab technician in 2000. Afterwards he joined Boehringer Ingelheim and worked in the department “Biopharmaceuticals” in the radionuclide laboratory. Here he characterized the binding of radionuclide labelled antibodies to cells and performed binding and...

Three decades his research focuses on the identification of prognostic/predictive epigenetic and molecular markers for clinical outcome, response to chemo-radiotherapy, gene-targeted therapy and treatment-resistance in lung, GIST, head&neck cancer, as well as the early detection of cervical...

Kawaldip is the CEO of the International Alliance of Patients' Organisations. He previously held the position of CEO at Richmond Psychosocial Foundation International and worked as Managing Director of Coram Children’s Legal Centre. He has European and international public health experience as...

Mr. Shea is a director in the Biotechnology/Chemical Practice Group at Sterne, Kessler, Goldstein & Fox P.L.L.C., where he has practiced for 20 years.  He specializes in advising biopharmaceutical companies and research institutions on complex legal issues relating to the...

Nigel Shipston Ph.D, ARCS, Director, Technical Marketing FUJIFILM Diosynth Biotechnologies Inc.Nigel Shipston is Director, Technical Marketing at Fujifilm Diosynth Biotechnologies (FDB). He is responsible for supporting the development and launch of new service offerings. He has 30 years’...

As Global Director Strategic Technologies at Cytiva, Fredrik is responsible for working with the pharmaceutical industry to improve current workflows with innovative analytical solutions and validation services. He also advises on R&D projects and business development activities. Fredrik is...

Ingrid Teige is VP preclinical Research at BioInvent, a Swedish Biotech developing antibody-based treatments for cancer immunotherapy. After her PhD in T cell immunology from Lund University, she joined LEO Pharma and their efforts at inhibiting chronic inflammation. In 2009, she shifted focus from ...

I have over 20 years of experience designing and developing different oncolytic viruses. This primarily includes pre-clinical and translational development but also early phase clinical testing. I have helped pioneer the use of these vectors alone, notably as immunotherapies and in combination with ...

Juliette Trepreau received her Ph.D. in Biochemistry from the Université de Grenoble. After a postdoc training at the Scripps Research Institute (Jupiter, FL, USA) she joined MimAbs, a french company specializing in immunotherapy antibodies to manage the recombinant mAb production platform. ...

Dr. Vafa joined TeneoBio as Chief Business Officer in February 2016. He has more than 15 years of global business and scientific experience in biotechnology and pharmaceutical drug discovery, asset evaluation, transactions and licensing. Prior to joining TeneoBio, Dr. Vafa was the Director of...

As an Application Scientist at ENPICOM, Néstor focuses on analyzing customer requirements, and project setup, management, and execution. During his PhD in Immunology, he isolated and expressed monoclonal antibodies after vaccinations and developed high-throughput sequencing library preparation...

Dr Vertès is Managing Director at NxR Biotechnologies, a boutique global consulting firm based in Basel, Switzerland, where he advises clients on strategy, business development, in/out-licensing, entrepreneurship and investment. He brings to his role extensive experience in the pharmaceutical and...

Éric Vivier, DVM, PhD, is Professor of Immunology at Aix-Marseille University and at the Public Hospital of Marseille (AP-HM). In addition, he was appointed in 2018, Scientific Director of Innate Pharma, a biotechnology company dedicated to improving cancer treatment with innovative therapeutic...

Chris Webster is a regulatory affairs consultant specialising in biologics and vaccines and principal of BioApprovals. Before founding BioApprovals, Chris led regulatory affairs groups at different companies for over 25 years, most recently heading biosimilars at Baxalta and previously leading...

Dr Michele Zagnoni leads a multidisciplinary research group focussed on the development of microfluidic and organ-on-a-chip technologies for healthcare applications, including fundamental biological research, drug screening and personalized medicine therapy (www.zagnonilab.com). He is the...

Before joining Pieris Pharmaceuticals as Director Immuno-Oncology overseeing pre-clinical development of Pieris´s innovative pipeline projects, Dr. Zettl was Project Leader at Boehringer-Ingelheim from 2011, leading antibody programs in the field of Immuno-Oncology from early preclinical into...

Dr. Zhang is a technical specialist at Sino Biological Europe, where she provides technical assistance of our recombinant protein and antibody products, as well as support of CRO services of recombinant protein production and antibody development for our customers. Before She joins our team in...

Jing joins Refuge Biotechnologies as Chief Business Officer following a wealth of experience in global healthcare transactions and financings. He has spent over a decade in pharmaceutical, biotech and healthcare finance working on a full spectrum of strategic transactions at big cap...